An Open-Label, Multicenter Dose-Escalation Study to Evaluate the Safety and Tolerability of AP 12009 (Trabedersen), Administered Intravenously in Patients With Advanced Tumors Known to Overproduce TGF-beta2.

Trial Profile

An Open-Label, Multicenter Dose-Escalation Study to Evaluate the Safety and Tolerability of AP 12009 (Trabedersen), Administered Intravenously in Patients With Advanced Tumors Known to Overproduce TGF-beta2.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Trabedersen (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Isarna Therapeutics
  • Most Recent Events

    • 06 Jun 2017 Results of phase II portion of this study (n=37) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 05 Apr 2017 Results of population pharmacokinetic model development for OT-101, presented at the 108th Annual Meeting of the American Association for Cancer Research
    • 21 Jan 2017 Results assessing association between plasma levels of 31 cyto-/chemokines and overall survival outcomes in pancreatic cancer patients treated with OT-101, presented at the 2017 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top